Interim report 2026
Filed with HKEX · Stock code 2616 · · 98 pages · English
Pages CORPORATE INFORMATION 2 FINANCIAL HIGHLIGHTS 4 BUSINESS HIGHLIGHTS 6 MANAGEMENT DISCUSSION AND ANALYSIS 11 DIRECTORS AND SENIOR MANAGEMENT 29 OTHER INFORMATION 38 REPORT ON REVIEW OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 68 CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME 69 CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION 70 CONDENSED CONSOLIDATE
Earlier from CStone Pharmaceuticals
- Voluntary announcement - increase in shareholding by CEO and executive director dr. jianxin yang by 496,000 shares, with accumulated purchase totaling 14,210,500 shares
- CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
- CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand
- CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights
- ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
Later from CStone Pharmaceuticals
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
- Voluntary announcement - cstone announces major clinical validation milestone for CS2009 at esmo 2026: data from more than 300 patients support mechanism, safety and broad antitumor activity
Follow CStone Pharmaceuticals into a list and get an email when it puts out news.
Follow CStone Pharmaceuticals